Clinical trials referenced in this document:
Documents that mention this clinical trial
Health-related quality of life after thrombectomy in young-onset versus older stroke patients: a multicenter analysis
CT perfusion to measure venous outflow in acute ischemic stroke in patients with a large vessel occlusion
Antithrombotic treatment and outcome after endovascular treatment and acute carotid artery stenting in stroke patients with atrial fibrillation
Predictors of independent outcome of thrombectomy in stroke patients with large baseline infarcts in clinical practice: a multicenter analysis
Intravenous thrombolysis upon flow restoration improves outcome in endovascular thrombectomy
Endovascular treatment of acute tandem lesions in patients with mild anterior circulation stroke
Thrombectomy in M2 occlusion compared to M1 occlusion: treatment effects of Thrombolysis In Cerebral Infarction (TICI) 2b and TICI 3 recanalization on functional outcome
Real world data in mechanical thrombectomy: who are we losing to follow-up?
Benefit and risk of intravenous alteplase in patients with acute large vessel occlusion stroke and low ASPECTS
How much of the outcome improvement after successful recanalization is explained by follow-up infarct volume reduction?
Early clinical surrogates for outcome prediction after stroke thrombectomy in daily clinical practice
Comparison of Thrombolysis In Cerebral Infarction (TICI) 2b and TICI 3 reperfusion in endovascular therapy for large ischemic anterior circulation strokes
Cerebral venous outflow profiles are associated with the first pass effect in endovascular thrombectomy
Circadian rhythm of ischaemic core progression in human stroke
Received: 23 May 2022
Accepted: 22 July 2022
First Online: 12 September 2022
: The study was centrally approved by the Institutional Review Board of the Ludwig-Maximilians-Universität Munich (protocol No. 689–15) and from local institutional review boards according to local regulations. Written informed consent was obtained in accord with local ethical approvals.
: Not applicable.
: JMW, JNM, SS, NMB, JN, CH, CB, FK, GCP, and FJB report no competing interests. FD received research funding from Cerenovus, speakers honorary from Cerenovus and Acandis and serves as a proctor and consultant for Cerus Endovascular, Balt and Cerenovus.